# A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia

Study · id `cardio:ct-nct04358432` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04358432](<https://clinicaltrials.gov/study/NCT04358432>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04358432

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 262 participants.

## Technical summary

Registry record NCT04358432. Randomized; triple masking; primary purpose treatment. Start 2020-05-13 (actual); primary completion 2021-02-25 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 262 participants (enrolled count; ClinicalTrials.gov record NCT04358432, source copy `cardio:ctgov-nct04358432-2023-03-02`, retrieved 2026-10-31)
- Started: 2020-05-13 (actual) (ClinicalTrials.gov record NCT04358432, source copy `cardio:ctgov-nct04358432-2023-03-02`, retrieved 2026-10-31)
- Primary completion: 2021-02-25 (actual) (ClinicalTrials.gov record NCT04358432, source copy `cardio:ctgov-nct04358432-2023-03-02`, retrieved 2026-10-31)
- Completion: 2021-02-25 (actual) (ClinicalTrials.gov record NCT04358432, source copy `cardio:ctgov-nct04358432-2023-03-02`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT04358432, source copy `cardio:ctgov-nct04358432-2023-03-02`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04358432-2023-03-02`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia
- Condition: Hypercholesterolemia
- Intervention (Drug): AK102
- Intervention (Drug): Placebos
- Intervention (Drug): Statins and/or Ezetimibe
- Lead sponsor: Akeso
- Lead sponsor class: INDUSTRY
- Collaborator: AD Pharmaceuticals Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Akeso (`cardio:org-akeso`)

## Provenance

Content hash: 3c48bffdf8135c7fd6fb9fbb310494792855b409e9788df57a26a30cc712b228
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
